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Postoperative nausea and vomiting (PONV) are still common following surgery. This is not only distressing to the patient, but
increases costs. The thorough understanding of the mechanism of nausea and vomiting and a careful assessment of risk factors
provide a rationale for appropriate management of PONV. Strategy to reduce baseline risk and the adoption of a multimodal
approach will most likely ensure success in the management of PONV.
1.Introduction
Postoperative nausea and vomiting (PONV) are two of the
most common and unpleasant side eﬀects following anaes-
thesia and surgery. The overall incidence of PONV has de-
creased from 60% when ether and cyclopropane were used,
to approximately 30% at present [1]. However, in certain
high-risk patients this incidence is still as high as 70%. It is
estimated that an episode of vomiting prolongs postanaes-
thetic care unit (PACU) stay by about 25 minutes [2]. Pa-
tientsnotonlyranktheabsenceofPONVasbeingimportant
[3],butalsorankitmoreimportantthananearlierdischarge
from an ambulatory surgical unit [4]. In one survey, patients
were willing to pay at their own expense, for a completely
eﬀective antiemetic [5]. Furthermore, it is estimated that
approximately 0.2% of all patients may experience intra-
ctable PONV, leading to a delay in recovery room discharge
and/or unanticipated hospital admission following ambula-
torysurgery,therebyincreasingmedicalcosts.Recentinterest
hasfocusedontheuseofacombinationofantiemeticsacting
at diﬀerent receptors and the adoption of a multimodal
approach to tackle this problem. This paper will discuss the
pathophysiology and risk factors of PONV, the use of multi-
modal approach, and novel therapy of PONV management.
Finally, recommendations for the prophylaxis and treatment
of PONV will also be discussed.
2. Anatomy
The neuroanatomical site controlling nausea and vomiting is
an ill-deﬁned region called the “vomiting center” within the
lateral reticular formation in the brainstem. The vomiting
center receives aﬀerent inputs from higher cortical centers,
the cerebellum, the vestibular apparatus, and vagal and
glossopharyngeal nerves. Further interactions occur with the
nucleustractussolitariusandthechemoreceptortriggerzone
(CTZ) which is located in the ﬂoor of the fourth ventricle.
The CTZ is outside the blood-brain barrier and in contact
with cerebrospinal ﬂuid (CSF). The CTZ enables substances
in the blood and CSF to interact. Direct stimulation of the
CTZdoesnotresultinvomiting.Immunochemicalstudiesof
these anatomical sites show that these areas contain hista-
mine, serotonin, cholinergic, neurokinin-1, and D2 dopa-
mine receptors (Figure 1).
3.Physiology [6]
The “vomiting reﬂex” is precipitated by diﬀerent stimulation
from the glossopharyngeal, hypoglossal, and vagal nerves
reaching the vomiting center. Eﬀerent signals are directed to
theglossopharyngeal,hypoglossal,trigeminal,accessory,and
spinal segmental nerves.There is a coordinated contraction
of abdominal muscle against a closed glottis, which raises2 Anesthesiology Research and Practice
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Figure 1: The inputs and receptors involved in causing PONV. 5 HT: 5- hydroxytryptamine/serotonin; GI: gastrointestinal.
intra-abdominal and intrathoracic pressures. The pyloric
sphincter contracts and the oesophageal sphincter relaxes,
and there is active antiperistalsis within the oesophagus,
which forcibly expels the gastric contents. This is associated
with marked vagal and sympathetic activity leading to sweat-
ing, pallor, and bradycardia.
4. Who Is at Risk for Postoperative Nauseane
andVomiting
The modern era in PONV risk factor research began in the
early 1990s, with publication of the initial studies that
attempted to simultaneously identify multiple risk factors.
The identiﬁcation of individual at high risk for PONV can
narrow the pool of potential candidates for prophylactic
antiemetic therapy, indicating those most likely to beneﬁt
and reducing antiemetic side eﬀects and costs for patients
unlikely to beneﬁt.
5.InAdults
Onlyafewriskfactorshaveconsistentlybeenshowntobein-
dependent predictors for PONV [7–12].
5.1. Patient-Related Independent Predictors
5.1.1. Female Gender. The reason for increased female sus-
ceptibility to nausea and vomiting is not clear. PONV in-
creases during menstruation and preovulatory phase of the
menstrual cycle due to sensitization of the chemoreceptor
trigger zone (CTZ) and vomiting center to follicle-stimulat-
ing hormone (FSH) and oestrogen. However, this gender
diﬀerence in PONV is not noticed in paediatric age group
and population aged more than 60 years.
5.1.2. Nonsmoking. Cohen et al. were the ﬁrst to determine
thatnonsmokers arealmosttwiceaslikely assmokerstohave
PONV [12]. Several other workers [13–16] have validated
thatﬁndingsofCohenetal.Chronicexposuretosmoke(par-
ticularly the polycyclic aromatic hydrocarbons) produces
changes in liver microsomal enzymes that may aﬀect the
metabolism of drugs used in the perioperative period and
the ability of these drugs to produce PONV. The protective
aspect of smoking on postoperative nausea and vomiting is
not likely to be attributable to an acute action of smoke
constituents.
5.1.3.HistoryofPONV,MotionSickness,orMigraine. Suscep-
tibility to emetogenic stimuli increases among individuals
with a personal history of PONV [10, 11], motion sickness,
or migraine [13–17].
5.1.4. Age. Among pediatric patients the incidence has been
shown to be as high as 34% in the 6–10 year age group but
considerably lower in younger patients, and the incidence
decreases with the onset of puberty. In adults, the incidence
of PONV appears to decrease with age [12, 15, 17, 18].
5.1.5.Obesity. Abodymassindexofmorethan30inpatients
had been associated with PONV. This may be due to an
increasedintra-abdominalpressureandthepharmacokineticAnesthesiology Research and Practice 3
eﬀects of lipophilic anesthetic agents having prolonged half-
lives in these patients. However, recent data [19] suggests
that BMI is not correlated with an increased risk for the
development of PONV. An increased BMI may increase the
incidence of PONV in patients with other independent risk
factors.
5.2. Anaesthesia-Related Independent Predictors
5.2.1.PostoperativeOpioids. Mostlargerstudiesdemonstrate
that use of postoperative opioids approximately doubles the
risk of PONV [7, 11, 14]. The total dose of postoperative
opioid [20], but not the particular type [21], appears to be of
relevance. However, opioid given to a patient already in pain
is not associated with signiﬁcant increase in PONV episodes.
Ultrashort-actingopioid-likeremifentanilhasbeenfoundto
have similar incidences of PONV as fentanyl over the ﬁrst 24
hour postoperative period [14, 22].
5.2.2. Inhalational Anaesthetics. There were no diﬀerences in
incidence of PONV among the individual volatile anaesthe-
tics (comparing halothane, isoﬂurane, sevoﬂurane, and des-
ﬂurane) at 1MAC or below [23–25]. However, volatile in-
duction maintenance anaesthesia (VIMA) is associated with
lesser PONV than balanced anaesthesia using opioids. Apfel
and colleagues [9] have demonstrated that volatile anaesthe-
tics are the main cause of PONV within the ﬁrst two post-
operative hours.
5.2.3. Nitrous Oxide (N2O). The emetogenic eﬀectofnitrous
oxide has received considerable attention in the literature
with numerous studies in the 1980s and meta-analyses in the
1990s emphasizing the increased incidence of PONV with
this agent [26]. However, in practice, the emetogenic eﬀects
of nitrous oxide and volatile anaesthetics are independent.
thatis,theyareadditiveandnotsynergisticoverlapping[14].
Bivariate analysis indicated that substituting propofol for a
volatile anesthetic reduced the risk of postoperative nausea
and vomiting by about 19 percent, whereas substituting
nitrogen for nitrous oxide reduced the risk by about 12 per-
cent [14]. In a prospective randomized study of 2050 pa-
tients avoidance of nitrous oxide and the concomitant in-
crease in inspired oxygen concentration decreases the inci-
dence of complications after major surgery, but does not sig-
niﬁcantly aﬀect the duration of hospital stay [27]. A recent
meta-analysis demonstrated an overall reduction in risk of
PONV of 20% by avoiding N2O, the absolute diﬀerence in
the incidence of PONV between the two groups is however
small (33% with N2O and 27% without N2O) [28].
5.2.4. Duration of Anaesthesia. The eﬀect of increasing dura-
tion of anaesthesia on PONV is described in a number of
studies[10,16,23].Theincidencemaybeincreasedwhenin-
halational anaesthetics are used and decreased when pro-
pofol is used and in addition depends on the amount of opi-
oids given. Increasing the operative duration by 30 minutes
may increase the risk of PONV by 60%.
5.3. Surgery-Related Independent Predictors. Although type
of surgery has been identiﬁed as a risk factor in numerous
reports, its status as such is still somewhat controversial; the
speciﬁc procedures implicated as particularly emetogenic
sometimesvaryamongstudies.Typesofproceduresthatmay
be viewed as possible risk factors include intraabdominal,
laparoscopic, orthopaedic, major gynaecological, ear nose
and throat (ENT), thyroid, breast, and plastic surgery as well
as neurosurgery. High rate of PONV in laparoscopy may be
caused by the gas used to “inﬂate” the abdomen to create
work place for the instruments. This puts pressure on the
vagusnerve,whichhasaconnectiontothebrain’snauseaand
vomiting center. In addition to this, patients undergoing day
case gynaecological laparoscopy have a number of other risk
factors for PONV, as female gender, use of perioperative
opioid, and a journey home which is likely to lower the
threshold to motion-induced emesis [29]. There was no sig-
niﬁcantdiﬀerencebetweentheriskofPONVafterlaparosco-
pic versus open cholecystectomy, and the eﬀect of laparo-
scopyremainedinsigniﬁcantafterriskadjustmentinagener-
alized linear regression model [30].
5.4. Other Factors. High levels of anxiety and postoperative
pain, especially of pelvic or visceral origin, may also lead to a
higher incidence of postoperative nausea and vomiting.
6.InPaediatrics
Paediatric patients are not spared from postoperative vomit-
ing, with peak incidence in schoolchildren of 34% to 50%
[31]. In this population, only vomiting is reported due to
diﬃculties in eliciting nausea in the young age group. It is
one of the leading postoperative complaints from parents
and the leading cause of readmission. Prior to puberty,
gender diﬀerences for postoperative vomiting (POV) have
not been identiﬁed [32, 33]. Operations associated with a
high incidence of postoperative vomiting in children include
strabismus, adenotonsillectomy, hernia repair, orchidopexy,
and penile surgery [34] .O t h e rr i s kf a c t o r sf o rP O Vi n
children are the same as those in adults, with several
important diﬀerences, POV increases as children grow up.
It is rare in children younger than 2 years old. However,
children aged more than 3 years have an average vomiting
incidence of ≥40%. The increased vomiting incidence tapers
when children reach puberty. Sex diﬀerences in risk of
vomiting in children include adenotonsillectomy, strabismus
repair, hernia repair, orchiopexy, and penile surgery [35].
Nonsteroidalanti-inﬂammatorydrugs(NSAIDS)suchas
ketorolac, as well as paracetamol which have a central mode
of action can reduce the need for opioids. Also, a multimodal
approach combining reduced dosages of narcotics and
NSAIDs allows potentiation of analgesic eﬀect and decreased
severity of complications from both groups. Use of rectal
acetaminophen and regional anaesthesia techniques (e.g.,
caudal epidural) in the paediatric population decrease the
use of perioperative opioids and consequently the incidences
of PONV.
Regarding use of antiemetics in the paediatric popula–
tion, eﬃcacy appears comparable to that known for adult.
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for antiemetics in adults, however, and even fewer in chil-
dren. Thus, most paediatric doses are somewhat arbitrarily
set at a fraction (1/5th to 1/25th) of the common adult dose
[31].
7.Postdischarge NauseaandVomiting(PDNV)
Inourcountry,signiﬁcantnumbersofsurgeriesarenowper–
formed on an outpatient basis. In addition to being a major
cause for lengthened stay and unanticipated admission,
PDNV may also pose a signiﬁcant problem to the patient
after discharge [36]. Numerous studies and consensus guide-
lines have been published on prevention of PONV, but few
have evaluated the eﬃcacy of prophylaxis on PDNV or its
impact on quality of living during recovery [1, 7, 23, 29].
Early ambulation has been reported to be a contributor to-
early emetic symptoms. Reported postdischarge nausea
(PDN) incidences varied from 0% to 55% and postdischarge
vomiting (PDV) incidences from 0% to 16% [23, 35–39].
However,itisnotclearwhethertheriskfactorsforPDNVare
the same as for PONV, or whether PONV in the postanaes-
thesia care unit (PACU) predicts PDNV [37, 38]. Carroll
et al. reported that outpatients who were discharged home
often chose to wait for resolution of emetic symptoms rather
than to contact their physicians for antiemetic treatment
[38]. Patient with PDNV are signiﬁcantly more likely to have
problems performing activities of living, have a lower satis-
faction score, and higher negative economic impact than are
those not experiencing PDNV [38].
Shorter-acting drugs are not as eﬀective, especially when
used at the minimally eﬀective dose, and that antiemetics
with a longer duration of action seem favourable. Therefore,
dexamethasone, transdermal scopolamine, palonosetron,
and the NK1-receptor antagonists may be reasonable ﬁrst
choices for the prevention of postdischarge nausea and
vomiting [40].
8. Risk Factor Findings
8.1.ScoringSystem. AnumberofPONVriskscoringsystems
have been developed. Using logistic regression analysis by
Palazzo and Evans, Koivuranta et al. generated a score based
on the predictive factors [41, 42]. Recently, Apfel et al.
developedasimpliﬁedriskscoreconsistingoffourpredictors
[7]. In adults, female gender, history of motion sickness or
PONV, nonsmoking status, and the use of opioids for intra-
operative or postoperative analgesia are used as risk factors
and 1(one) point against each factor (Figure 2).
In children, surgery >30 minutes, age ≥3y e a r s ,s t r a b i s -
mus surgery, and history of POV or PONV in relatives with
1(one) point against each factor [43]a r eu s e d( Figure 3).
Despite the limitations in accuracy of PONV risk scoring
system, their use to better tailor antiemetic interventions has
been shown to signiﬁcantly reduce the incidence of PONV
in general and particularly in high risk patient populations,
while avoiding the expense and potential side eﬀects of
prophylactic antiemetics in lower-risk individuals [44].
Table 1: Anaesthetic strategies to decrease PONV.
(1) Use of regional anaesthesia.
(2) Avoid emetogenic stimuli
(a) Nitrous oxide
(b) Inhalational agents
(c) Etomidate and Ketamine.
(3) Minimize the following:
(a) Intraoperative and postoperative opioids
(b) Adequate analgesia incorporating local anaesthetics,
NSAIDs, and opioid as required
(c) Limiting the dose of neostigmine to 2.5mg in adults.
(4) To consider the following:
(a) Total intravenous anaesthesia (TIVA) with propofol
(b) Adequate hydration, especially with colloids.
(c) Use of intraoperative supplemental oxygen
(d) Use of a anxiolytics, for example, benzodiazepines
(e) Nonpharmacological techniques, for example, acupunc-
ture.
9.IntraoperativeAnaestheticManagement
To decrease the incidence of PONV without compromising
on analgesia, regional anaesthesia is to be used whenever
possible to minimise the intake of opioids. Emetogenic
induction agents like nitrous oxide, inhalational agents,
and etomidate and ketamine are avoided in patients with
serious risk of PONV. Other strategies may be to supplement
analgesia with NSAIDs and regional anaesthesia to decrease
the usage of perioperative opioids. Anticholinesterases like
neostigmine should always be used in appropriate dosage
after conﬁrming reversal characteristics with use of neuro-
muscular monitoring.
Other strategies may be to use total intravenous anaes-
thesia (TIVA) with propofol, prevention of hypotension,
adequately hydrate and oxygenate the patient, and sedate
an anxious patient taking a multimodal approach to PONV
management. Some studies have stated that nonpharma-
cologic strategies like acupuncture reduce the incidence of
PONV. These strategies are summarized in Table 1.
10. CurrentlyAvailable Antiemetics [45]
There are at least four major receptor systems involved
in the aetiology of PONV. Currently, available antiemetics
may act at the cholinergic (muscarinic), dopaminergic
(D2), histaminergic (H1), or serotonergic (5HT3) receptors.
Neurokinin-1(NK-1) receptor antagonists are also being
investigated. Cholinergic receptors are found in the vomiting
center and vestibular nuclei. The area postrema is rich in
dopamine(D2),opioid,andserotonin(5HT3)receptors.The
nucleus tractus solitaries is rich in enkephalins and in his-
taminic (H1), muscarinic cholinergic, and NK-1 receptors.
the latter are also found in the dorsal motor nucleus of the
vagus nerve.Anesthesiology Research and Practice 5
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Figure 2: Simpliﬁed risk score for PONV in adults. (Reproduced from the original article by Gan et al. [52]).
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Ondansetron, granisetron, dolasetron, tropisetron, and
other serotonin antagonists have been shown to provide
eﬀective treatment and prophylaxis of PONV and are asso-
ciated with a low incidence of side eﬀe c t s .T h e s ea g e n t sa r e
notdopamine,muscarinic,orhistaminereceptorantagonists
and, as such, are not associated with the side eﬀects common
to those classes. Side eﬀects common to the serotonin antag-
onistsincludeheadache,lightheadedness,dizziness,andcon-
stipation.
Metoclopramide acts on both central dopamine and
serotonin receptors, and has both prokinetic and antiemetic
eﬀects. Metoclopramide increases gastrointestinal tract mot-
ility, decreases gastric emptying time and gastric volume, in-
creases lower esophageal sphincter tone, and is usually well
tolerated in adults. Extrapyramidal eﬀects and dystonia are
more often seen in the pediatric population.
Dexamethasone is an eﬀective antiemetic though its
mechanism of action remains uncertain. Most likely mech-
anisms are prostaglandin inhibition in peripherally, with
facilitation of serotonergic antagonism and endorphin rel-
ease centrally. Its long duration of action and cost eﬀective-
ness make dexamethasone an attractive choice in the PONV
management.
Droperidol is a butyrophenone eﬀective in the treatment
of PONV. Like the phenothiazines, droperidol acts compet-
itively on central dopaminergic receptors and is associated
withsedation,lethargy,agitation,andextrapyramidaleﬀects.
The “black box” warning to the droperidol drug information
sheet by the FDA has reduced the use of droperidol to that of
rescue agent for intractable cases of PONV. A prolonged QTc
interval develops in some patients putting them at risk to
develop torsade de pointes. Despite the limited evidence that
antiemetic doses trigger this dangerous arrhythmia, electro-
cardiographic monitoring remains mandatory whenever this
drug is being used, and needs to be used for 2 to 3 hours after
its use.
Ephedrine and other agents that help maintain blood
pressure may be used to prevent the nausea associated with
hypotension postoperatively.6 Anesthesiology Research and Practice
Table 2: Antiemetic doses and timing for administration in adults.
Drug Dose Timing
Ondansetron 4–8mg IV At end of surgery
Dolasetron 12.5mg/IV At end of surgery
Granisetron 0.35–1mg IV At end of surgery
Tropisetron 5mg IV At end of surgery
Dexamethasone 5–10mg IV At induction
Droperidol 0.625–1.25mg IV At end of surgery
Ephedrine 1–2mg/KG IV At end of surgery
Prochlorperazine 5–10mg IV At end of surgery
Promethazine 12.5–25mg IV At end of surgery
Scopolamine Transdermal patch Applied prior evening or 4hr before end of surgery
Based on the original article by Gan et al. [52].
Table 3: Antiemetic doses for prophylaxis of postoperative vomit-
ing (POV) in children.
Drug Dose
Dexamethasone 150µg/Kg up to 5mg
Dimenhydrinate 0.5mg/Kg up to 25mg
Dolasetron 350µg/kg up to 12.5mg
Droperidola 10–15µg/Kg up to 1.25mg
Granisetron 40µg/Kg up to 0.6mg.
Ondansetronb 50–100µg/Kg up to 4mg.
Perphenazine 70µg/Kg up to 5mg
T r o p i s e t r o n 0 . 1m g / K gu pt o2m g .
aSee food and drug administration (FDA) “black box” warning.
Recommended doses 10 to 15µg/Kg.
bApproved for POV in paediatric patients aged one month and older.
Reproduced from the original article by Gan et al. [52].
Promethazine, prochlorperazine, and chlorpromazine
are phenothiazines that exert their antiemetic eﬀects by dir-
ectly acting on the central dopaminergic receptors of the
chemoreceptor trigger zone. These agents are most eﬀective
in the treatment of opioid-induced PONV, but their use as
the primary treatment for PONV is limited by their tendency
to cause sedation.
Scopolamine is an anticholinergic agent that acts on the
muscarinic and histaminic receptors of the vestibular appa-
ratus and the nucleus of the tractus solitarus to reduce the
incidence of PONV. It has been found to be very eﬀective in
patients treated with opioids for postoperative pain control
and after middle ear surgery, though use is limited by a
high incidence of sedation and dry mouth. Scopolamine, in
the form of a transdermal patch applied the evening before
or the morning of surgery, has been shown to reduce the
incidence of PONV as eﬀectively as ondansetron. It is eﬀec-
tive if applied the evening before surgery or 4h before the
end of anesthesia due to its 2–4h onset of eﬀect.
Placement of capsaicin ointment on the K-D2 point (the
Korean hand acupressure point in Koryo Hand Therapy) of
both hands 1h before laparoscopic cholecystectomy resulted
in a signiﬁcantly lower incidence of PONV, and the need for
rescue antiemetic treatment was also lower. Stimulation of
the P6 acupressure point has been associated with decreased
postoperative nausea and vomiting in high risk women and
has also been shown to increase patient tolerance to experi-
mental nauseogenic stimuli, as well as reducing the number
of symptoms experienced.
Current pharmacotherapies available for the manage-
ment of PONV and POV are summarized in Tables 2 and
3.
11. Recommended Strategy for
PONV Prophylaxis
The risk of PONV should be estimated for each patient.
No prophylaxis is recommended for patients at low risk for
PONV except if they are at risk for medical consequences
from vomiting, for example, patients with wired jaws or
increased intracranial pressure or who are having fundopli-
cations surgery. For patients at moderate to high risk for
PONV, regional anaesthesia should be considered. If this is
not possible or contraindicated and a general anaesthesia
is used, strategies to minimize the baseline risk of PONV
shouldbeadopted.Theuseofcombinationantiemeticthera-
py and more appropriately a multimodal approach includes
use of two or more interventions. A multimodal approach
to minimize PONV combines pharmacologic and nonphar-
macologic prophylaxis as well as interventions that reduce
baseline risk.
Ingeneral,combinationtherapyissuperiortomonother-
apy for PONV prophylaxis. Drugs with diﬀerent mechanism
of action should be used in combination to optimize eﬃcacy
[46–48].
12. Recommended Strategy for PONV Who Did
Not ReceiveProphylaxisorinWhom
ProphylaxisFailed
When persistent nausea and vomiting occur after the patient
has left the postanaesthesia care unit, the ﬁrst response
should be a bedside examination to exclude an initiating
medication or mechanical factor. Contributing factor might
include patient-controlled analgesia with morphine, bloodAnesthesiology Research and Practice 7
draining down the throat, or an obstruction of the gut.
Oncemedicationandmechanicalfactorsareexcluded,rescue
antiemetic therapy can be initiated.
If a patient has received no prophylaxis, therapy with
small dose 5HT3 receptor antagonists should be initiated on
the ﬁrst sign of PONV. Small-dose therapy includes ondan-
setron1mg,dolasetron12.5mg,granisetron0.1mg,andtro-
pisetron 0.5mg. For all other antiemetics, data on their ther-
apeutic eﬃcacy are sparse, and optimal doses are unknown
[49].
When prophylaxis with dexamethasone fails to prevent
PONV, treatment within a small dose 5-HT3 receptor antag-
onist has been recommended [42]. When prophylaxis with a
5-HT3 antagonist is inadequate to prevent PONV, a 5-HT3
antagonist should not be initiated as rescue therapy within
theﬁrst6hoursaftersurgerybecauseitconfersnoadditional
beneﬁt [50]. Similarly, the failure of prophylaxis with a 5-
HT3 antagonist plus dexamethasone should be treated with
a drug from another class, for instance, droperidol or pro-
methazine.
A triple-therapy dosing regimen (for instance, a 5-HT3
antagonist, droperidol, and dexamethasone) has never been
tested. If the patient experiences PONV despite triple pro-
phylaxis, the triple regimen should not be repeated within
the ﬁrst 6 hours of administration, and an alternative anti-
emetics should be administered. Propofol 20mg as needed
can be considered for rescue therapy in patients still in the
postanaesthesia care unit [51]. The antiemetic eﬀect with
small doses of propofol is probably brief.
When PONV occurs more than 6 hours after surgery,
repeat dosing of 5-HT3 antagonists and droperidol can be
considered. The optimal dose and interval for readministra-
tion of these two antiemetics remain unknown.
13. Combination Antiemetic Therapy
None of the available antimetics is entirely eﬀective for pre-
venting PONV, especially in high-risk patients. Since at least
four major receptor systems are involved in the aetiology
of PONV, a better prophylaxis might be achieved by using
a combination of agents acting at diﬀerent receptor sites.
For example, if the serotonin receptors have already been
blocked, consider adding an anticholinergic, antidopaminer-
gic,orantihistamine.Theconceptofcombinationantiemetic
therapy was ﬁrst introduced in chemotherapy induced vom-
iting. Its success prompted similar research in the ﬁeld of
PONV [46, 47].
The most commonly studied combinations have includ-
ed a 5-HT3 receptor antagonist with either droperidol or
dexamethasone. Both combination regimens appear to be
equally eﬃcacious [46–48].
Combination therapy is most cost eﬀective for patients at
high risk for the development of PONV, and medium risk
patients are often successfully treated with a single agent.
Increasing the number of antiemetics administered reduced
the incidence of postoperative nausea and vomiting from 52
percent when no antiemetics were used to 37 percent,
28 percent, and 22 percent when one, two, and three
antiemetics, respectively, administered, which corresponds
to a 26 percent reduction in the relative risk of nausea and
vomiting for each additional antiemetic used [14].
14. Multimodal Approach[52]
In addition to using a combination of antiemetics acting at
diﬀerent receptor sites, the multifactorial aetiology of PONV
might be better addressed by the adoption of multimodal
approach.
A multimodal approach to minimize PONV combines
nonpharmacologic and pharmacologic prophylaxis as well as
interventions that reduce baseline risk [1, 50, 51]. Scuderi
et al. [50] tested the eﬃcacy of a multimodal approach to
reducing PONV. Their multimodal approach consisted of
preoperativeanxiolysisandaggressivehydration(25mL/Kg),
oxygen, prophylactic antiemetics (droperidol, 0.625mg and
dexamethasone, 10mg at induction and ondansetron, 1mg
at end of surgery) total intravenous anaesthesia with propo-
folandremifentanil,andketorolac(30mg).Nonitrousoxide
or neuromuscular blockade was used. Patients who receiv-
ed multimodal therapy had a 98% complete response rate
(no PONV and no rescue antiemetic) compared with 76%
response rate among patients receiving antiemetic mono-
therapy and a 59% response rate among those receiving rou-
tine anaesthetic plus saline placebo.
15. Novel Antiemetics
15.1. Neurokinin-1 Antagonists. Substance P, a member of
the tachykinin family of neuropeptides is an important neu-
rotransmitter in aﬀerent pathways of emesis [52]. Substance
Pmaybereleasedfromenterochromaﬃncellsinthestomach
and intestine (e.g., postoperative trauma) or from sensory
neurons (e.g., radiation, chemotherapeutic agents) [53]. The
NKI receptors are located in the area postrema and are
thoughttoplayaparticularlyimportantroleinemesis.How-
ever, NK1 receptor antagonists (NK1 RAS) are thought to
exert their mechanism of action on neurons in the “aﬀerent
relay station” situated between the medial neurotransmitter
system and the central pattern generator for vomiting [53]
although this has not been deﬁnitely isolated for humans.
The potential NK1 receptor blocking activity located deeper
in the brain stem is thought to prevent both acute and delay-
ed emesis, whereas 5-HT3 receptor antagonists are largely
eﬀective only against acute emesis [53], leading to consid-
erable recent interest in the use of NK1 receptor antagonists
for prophylaxis of PONV.
Aprepitant is the only NK1 receptor antagonist currently
approved by the FDA for the prophylactic management for
PONV. It is available in oral capsule in 40mg to be admin-
istered between 1–3 hours before surgery. It has a long half-
lifeofabout48hours[54].Itappearstohavebettereﬃcacyin
the prevention of PONV when compared with ondansetron
[55].
15.2.Long-ActingSerotoninAntagonist. Palonosetronhasthe
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serotonin antagonists at about 40 hours [53]. Its long dura-
tion of action can also be explained by its high binding
aﬃnity for 5-HT3 receptors [54]. It is 62% bound to plasma
proteins [56].
The liver metabolizes approximately 50% of palonoset-
ron. The two primary metabolites, N-oxide-palonosetron
and 6-(s)-hydroxyl-Palonosetron, are essentially inactive
[56].
16. Suggested Regimen
Once the patient is placed into the proper risk group, then
speciﬁc recommendations can be made regarding proper
care.
(1) No prophylaxis is recommended for patients at low-
risk for PONV except if they are at risk for medical
consequences from vomiting, for example, patients
with wired-jaw.
(2) Inmoderateriskpatients,ifprophylacticdoseofdex-
amethasone fails, then a serotonin antagonist should
be used as soon as nausea or vomiting occurs. If
treatment with this single agent fails, then aggressive
and properly chosen combination therapy should be
utilized.However,thebestavailablecombinationand
theoptimumdosesofantiemeticagentswhenusedin
combination are yet to be established.
(3) Inhigh-riskpatients,dexamethasoneplusaserotonin
antagonist should be utilized for prophylaxis. If this
prophylaxis fails, aggressive and properly chosen
combination therapy should be utilized.
(4) There is paucity of data on the use of antiemetics for
the treatment of PONV in patients who failed pro-
phylaxis or did not receive prophylaxis. This is due
to the diﬃculty in performing such studies since a
large number of patients would need to be recruited
in order to obtain the required target of patients who
eventually experience PONV.
The 5-HT3 receptor antagonists were the most common-
ly tested drugs in rescue clinical trials. Similar to their use in
PONV prophylaxis, the antivomiting eﬃcacy of the 5-HT3
receptor antagonists is more pronounced than their antin-
ausea eﬃcacy. There is no evidence of dose responsiveness
for those agents when used for rescue. Therefore, small doses
of these agents have been recommended for treatment: on-
dansetron 4mg, granisetron 0.1mg, dolasetron 12.5mg, and
tropisetron 0.5mg.
17. Conclusion
Without prophylactic intervention, PONV will develop in an
estimated one third of patients (range, 10% to 80%) who
undergo inhalational anaesthesia. The consequences of
PONV include delayed discharge from the PACU, unantic-
ipated hospital admission, increased incidence of pulmonary
aspiration, and signiﬁcant postoperative discomfort. The
ability to identify high-risk patients for prophylactic inter-
vention can signiﬁcantly improve the quality of patient care
and satisfaction in the PACU.
Therefore, depending upon the level of risk, prophylaxis
should be initiated with monotherapy or combination ther-
apy [8]. All prophylaxis in children at moderate or high risk
for postoperative vomiting should include combination
therapy using a 5-HT3 antagonist and a second drug from
otherclass.Becausetheeﬀectsofinterventionsfromdiﬀerent
drug classes are additive, combining interventions has an ad-
ditive eﬀect in risk reduction.
When rescue therapy is required, the antiemetic should
be chosen from a diﬀerent therapeutic class than the drugs
used for prophylaxis.
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